Amgen VP of Investor Relations Arvind Sood to Present at the Baird Growth Stock Conference
More News related to AMGN
- Deutsche Bank Comments on Recent Strength in Amgen (AMGN), Cites Positive Buy-Side Meetings
- VLST Corporation Appoints Internationally Recognized Researcher Paul J. Carter, Ph.D. as Chief Scientific Officer
- New Data Show Preemptive Treatment May Significantly Reduce Skin Toxicities in Patients Receiving Vectibix(R) (Panitumumab)
- SAFE-BioPharma Roaming Digital ID Is First to Be Accepted by Federal Bridge
- Amgen and Wyeth Statement on Outcome of Dermatologic and Ophthalmic Drugs Advisory Committee (DODAC) Meeting
More News related to Press Releases
- America I AM Mobile Experience Begins Nationwide Tour
- USAID Administrator Officiates at Vietnam Mission Opening
- Austral Pacific Reports Results of A6 Well Drilling and Notification of Waihapa Production Station Temporary Shut Down
- VIDEO FEED: Governor Rendell Signs New State Budget
- NBA Star Set to Marry for 13th Time in Lavish Ceremony Atop World Famous Space Needle
THOUSAND OAKS, Calif.--(BUSINESS WIRE)--
Amgen (NASDAQ: AMGN) Vice President of Investor Relations Arvind Sood will present at the RW Baird Growth Stock Conference on Wednesday, May 14, 2008 beginning at 8:55 a.m. Central Time. Live audio of the presentation will be available over the Internet and can be accessed from Amgen's Web site, www.amgen.com, under Investors.
Information regarding presentation time, webcast availability, and webcast links are noted on Amgen's Investor Relations Events Calendar.
About Amgen
Amgen discovers, develops, manufactures and delivers innovative human therapeutics. A biotechnology pioneer since 1980, Amgen was one of the first companies to realize the new science's promise by bringing safe and effective medicines from lab, to manufacturing plant, to patient. Amgen therapeutics have changed the practice of medicine, helping millions of people around the world in the fight against cancer, kidney disease, rheumatoid arthritis, and other serious illnesses. With a deep and broad pipeline of potential new medicines, Amgen remains committed to advancing science to dramatically improve people's lives. To learn more about our pioneering science and our vital medicines, visit www.amgen.com.
Source: Amgen
Related Categories
Press ReleasesStocks Mentioned
+2.00Related Entities
Sign up for StreetInsider Free!
Recieve full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
